Sotac Pharmaceuticals

Sotac Pharmaceuticals Net Debt

The Net Debt of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 23, 2026 is 414.44 M INR. In the previous year, Net Debt was 215.00 M INR — a change of 92.76% (higher).

Net Debt

414.44 MINR

YoY

92.76%

Last updated:

Net Debt of Sotac Pharmaceuticals is 2025 414.44 M INR. Net Debt of Sotac Pharmaceuticals was 2024 215.00 M INR. It decreases by 92.76% higher compared to the previous year.

The Sotac Pharmaceuticals Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2020
128.59 M INR
Jan 1, 2021
166.91 M INR
Jan 1, 2022
73.60 M INR
Jan 1, 2024
215.00 M INR
Jan 1, 2025
414.44 M INR
The Sotac Pharmaceuticals Net Debt history
YEARNet DebtYoY
414.44 MINR+92.76%
215.00 MINR+192.12%
73.60 MINR-55.90%
166.91 MINR+29.80%
128.59 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Net Debt of Sotac Pharmaceuticals is 414.44 M INR in 2025.

Net Debt of Sotac Pharmaceuticals changed from 215.00 M INR to 414.44 M INR, representing a 92.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Sotac Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals